SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw some unusual options trading on Tuesday. Investors bought 75,479 call options on the stock. This represents an increase of approximately 114% compared to the typical daily volume of 35,245 call options.

Analyst Upgrades and Downgrades

SLS has been the subject of a number of research analyst reports. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, SELLAS Life Sciences Group has a consensus rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Price Performance

Shares of SLS stock traded down $1.00 during trading hours on Tuesday, reaching $9.84. The company had a trading volume of 6,109,073 shares, compared to its average volume of 8,483,030. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -42.57 and a beta of 2.42. SELLAS Life Sciences Group has a 12 month low of $1.39 and a 12 month high of $15.88. The business has a fifty day simple moving average of $10.43 and a 200-day simple moving average of $6.70.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Institutional Trading of SELLAS Life Sciences Group

Institutional investors have recently made changes to their positions in the company. Dagco Inc. grew its stake in shares of SELLAS Life Sciences Group by 19.8% in the 2nd quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock worth $18,191,000 after acquiring an additional 203,653 shares in the last quarter. Bank of America Corp DE lifted its position in shares of SELLAS Life Sciences Group by 535.7% during the first quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock valued at $2,714,000 after purchasing an additional 540,748 shares in the last quarter. California State Teachers Retirement System boosted its holdings in SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after purchasing an additional 1,709 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in SELLAS Life Sciences Group by 20.2% during the first quarter. The Manufacturers Life Insurance Company now owns 45,691 shares of the company’s stock worth $193,000 after purchasing an additional 7,673 shares during the last quarter. Finally, Quantinno Capital Management LP bought a new stake in SELLAS Life Sciences Group in the 1st quarter worth about $315,000. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.